Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

High- vs. low-dose enalapril compared for immunological effects in CHF

Feb. 21, 2000

Adenosine A1 antagonists as alternatives to diuretics in CHF

Feb. 18, 2000

UCSD researchers report fundamental breakthrough in treating, preventing shock

Feb. 18, 2000

Promising new atherosclerosis treatment expected to enter clinical trials later this year

Feb. 18, 2000

Acute and subchronic testing in mice indicates limited systemic toxicity for GLG-V-13

Feb. 17, 2000

Pharmacyclics' texaphyrins now claimed for use in macrophage-mediated conditions

Feb. 17, 2000

Guanylate cyclase-activating agents in early development at Aventis

Feb. 17, 2000

Alexion and Brigham & Women's Hospital to develop novel antiinflammatory antibody

Feb. 17, 2000

Novel gene therapy reverses atherosclerotic process in mice

Feb. 17, 2000

German researchers disclose new agents for hypertension

Feb. 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...